Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Year in Review: The 8 Most Important Lab Compliance Stories of 2023
Though things appeared status quo in 2023, last year may prove to be a turning point for the laboratory industry.
Dx Deal Roundup: Top 10 Clinical Lab M&A Deals of 2023
An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.
FDA Watch: Key Lab Test Clearances of 2023
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
Inside the Lab Industry: Q3 Earnings Signal Beginning of the End of ‘COVID-19 Hangover’
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
A Modern Healthcare Collaboration
Labs, patients, and technology must all work together to deliver forward-thinking patient-centered care.
January 2024 Labs in Court
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
Expert Q&A: 2023 Lab Industry Highs and Lows, and 2024 Outlook
Robin Divine, MBA, president and CEO of TriCore Reference Laboratories, discusses key recent developments in the lab industry and predictions for 2024.
The Future of Laboratory-Developed Tests
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
AI in Healthcare: What Do Recent Developments Mean for Labs?
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.
Diagnostics Pipeline: FDA Opens Path for Blood Tests Assessing Genetic Cancer Risk
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.